Trained innate immunity as a potential link between preeclampsia and future cardiovascular disease.

Ivo Carrasco-Wong, Javiera M Sanchez, Jaime A Gutierrez, Delia I Chiarello
Author Information
  1. Ivo Carrasco-Wong: Escuela de Tecnolog��a M��dica, Facultad de Medicina y Ciencia, Universidad San Sebasti��n, Santiago, Chile.
  2. Javiera M Sanchez: Escuela de Tecnolog��a M��dica, Facultad de Medicina y Ciencia, Universidad San Sebasti��n, Santiago, Chile.
  3. Jaime A Gutierrez: Escuela de Tecnolog��a M��dica, Facultad de Medicina y Ciencia, Universidad San Sebasti��n, Santiago, Chile.
  4. Delia I Chiarello: Escuela de Tecnolog��a M��dica, Facultad de Medicina y Ciencia, Universidad San Sebasti��n, Santiago, Chile.

Abstract

preeclampsia (PE) is a complex pregnancy syndrome characterized by hypertension with or without proteinuria, affecting 2-6% of pregnancies globally. PE is characterized by excessive release of damage-associated molecular patterns (DAMPs) into the maternal circulation. This DAMP-rich milieu acts on innate immune cells, inducing a proinflammatory state characterized by elevated cytokines such as IL-1�� and IL-18. This proinflammatory state in the mother and placenta results in the endothelial dysfunction strongly associated with cardiovascular disorders. While the immediate maternal and fetal risks of PE are well-documented, accumulating evidence indicates that PE also confers long-term cardiovascular risks to the mother, including hypertension, coronary heart disease, stroke, and heart failure. The underlying mechanisms connecting PE to these chronic cardiovascular conditions remain unclear. This article explores the potential role of trained innate immunity (TRIM) as a mechanistic link between PE and increased long-term cardiovascular risk. We propose that the persistent exposure to DAMPs during PE may epigenetically reprogram maternal innate immune cells and their progenitors, leading to TRIM. This reprogramming enhances the inflammatory response to subsequent stimuli, potentially contributing to endothelial dysfunction and chronic inflammation that predispose women to cardiovascular diseases later in life. Understanding the role of TRIM in PE could provide novel insights into the pathophysiology of PE-related cardiovascular complications and identify potential targets for therapeutic intervention. Further research is warranted to investigate the epigenetic and metabolic alterations in innate immune cells induced by PE and to determine how these changes may influence long-term maternal cardiovascular health.

Keywords

References

  1. Best Pract Res Clin Obstet Gynaecol. 2019 Oct;60:87-96 [PMID: 31311760]
  2. J Reprod Immunol. 2012 Jun;94(2):131-41 [PMID: 22542910]
  3. Blood. 2014 Jan 16;123(3):377-90 [PMID: 24277079]
  4. Am J Transplant. 2013 Dec;13(12):3123-31 [PMID: 24103111]
  5. Front Immunol. 2020 Mar 20;11:484 [PMID: 32265930]
  6. Circulation. 2016 Aug 23;134(8):611-24 [PMID: 27496857]
  7. Biomed Res Int. 2018 Nov 11;2018:2703518 [PMID: 30534554]
  8. J Mol Med (Berl). 2020 Jun;98(6):819-831 [PMID: 32350546]
  9. Circulation. 1983 May;67(5):1016-23 [PMID: 6831665]
  10. Life (Basel). 2023 Nov 29;13(12): [PMID: 38137878]
  11. Heart. 2023 Feb 23;109(6):449-456 [PMID: 36270786]
  12. BJOG. 2003 Apr;110(4):383-91 [PMID: 12699800]
  13. J Cell Physiol. 2017 Jul;232(7):1862-1871 [PMID: 27925202]
  14. Saudi Med J. 2000 Feb;21(2):190-2 [PMID: 11533780]
  15. Hum Reprod Update. 2012 Jul;18(4):458-71 [PMID: 22523109]
  16. N Engl J Med. 2004 Feb 12;350(7):672-83 [PMID: 14764923]
  17. Cancer Biol Ther. 2024 Dec 31;25(1):2425127 [PMID: 39513594]
  18. Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):2247-52 [PMID: 24390544]
  19. Am J Obstet Gynecol. 2005 Jul;193(1):227-33 [PMID: 16021084]
  20. Thromb Haemost. 2018 Dec;118(12):2064-2073 [PMID: 30453347]
  21. Cell Rep. 2016 Dec 6;17(10):2562-2571 [PMID: 27926861]
  22. J Am Soc Nephrol. 2012 Aug;23(8):1375-88 [PMID: 22677551]
  23. Biomolecules. 2023 Nov 13;13(11): [PMID: 38002326]
  24. JACC Basic Transl Sci. 2020 Jul 27;5(7):735-749 [PMID: 32760860]
  25. Nat Rev Immunol. 2020 Feb;20(2):95-112 [PMID: 31558839]
  26. Annu Rev Immunol. 2013;31:563-604 [PMID: 23516985]
  27. Front Immunol. 2017 Jun 28;8:760 [PMID: 28702032]
  28. Immunity. 2013 Jan 24;38(1):79-91 [PMID: 23273845]
  29. Cell Host Microbe. 2020 Aug 12;28(2):322-334.e5 [PMID: 32544459]
  30. Nat Rev Cardiol. 2020 Jun;17(6):327-340 [PMID: 31996800]
  31. J Endocrinol. 2017 Jan;232(1):R27-R44 [PMID: 27729465]
  32. Cell Host Microbe. 2018 Jan 10;23(1):89-100.e5 [PMID: 29324233]
  33. Nat Immunol. 2017 Jun;18(6):622-632 [PMID: 28459433]
  34. PLoS One. 2020 Feb 24;15(2):e0229332 [PMID: 32092105]
  35. J Pregnancy. 2012;2012:179827 [PMID: 23304511]
  36. Trends Immunol. 2019 Jan;40(1):1-11 [PMID: 30503793]
  37. Nat Rev Mol Cell Biol. 2010 Aug;11(8):579-92 [PMID: 20651708]
  38. Arterioscler Thromb Vasc Biol. 2016 Apr;36(4):e26-31 [PMID: 27010027]
  39. Front Immunol. 2021 Oct 22;12:699563 [PMID: 34745089]
  40. J Am Soc Nephrol. 2007 Feb;18(2):414-20 [PMID: 17229906]
  41. Front Immunol. 2018 Jul 20;9:1659 [PMID: 30079067]
  42. Cardiovasc Res. 2011 Feb 15;89(3):671-9 [PMID: 21139021]
  43. Cells. 2023 Jul 31;12(15): [PMID: 37566060]
  44. Int Immunopharmacol. 2023 Jan;114:109523 [PMID: 36508916]
  45. Int J Cardiol. 2016 Jun 15;213:8-14 [PMID: 26316329]
  46. Front Immunol. 2014 Sep 25;5:461 [PMID: 25309543]
  47. Cureus. 2022 Feb 28;14(2):e22711 [PMID: 35386146]
  48. Connect Tissue Res. 2019 Mar;60(2):117-127 [PMID: 29658360]
  49. Front Cell Dev Biol. 2023 Jan 05;10:1099038 [PMID: 36684420]
  50. Diabetes Metab. 2012 Jun;38(3):183-91 [PMID: 22252015]
  51. Mol Med. 2015 Oct 27;21 Suppl 1:S6-S12 [PMID: 26605648]
  52. Congest Heart Fail. 2008 Jan-Feb;14(1):31-6 [PMID: 18256567]
  53. Hypertension. 2001 Oct;38(4):803-8 [PMID: 11641290]
  54. Front Immunol. 2024 Apr 23;15:1376421 [PMID: 38715619]
  55. Hippokratia. 2013 Apr;17(2):141-5 [PMID: 24376319]
  56. Placenta. 2009 Jun;30(6):473-82 [PMID: 19375795]
  57. Arterioscler Thromb Vasc Biol. 2014 Aug;34(8):1731-8 [PMID: 24903093]
  58. Front Cardiovasc Med. 2022 Jul 07;9:897771 [PMID: 35872915]
  59. BMC Immunol. 2010 Dec 02;11:59 [PMID: 21126355]
  60. FASEB J. 2012 Dec;26(12):4876-85 [PMID: 22919072]
  61. PLoS One. 2015 Jun 08;10(6):e0129095 [PMID: 26053021]
  62. Cytokine. 2008 Jan;41(1):9-15 [PMID: 18023202]
  63. Nat Rev Dis Primers. 2023 Feb 16;9(1):8 [PMID: 36797292]
  64. Stroke. 2010 Nov;41(11):2625-31 [PMID: 20930164]
  65. Blood. 2017 Feb 23;129(8):1021-1029 [PMID: 27919911]
  66. J Immunol. 2024 Nov 1;213(9):1292-1304 [PMID: 39302114]
  67. J Immunol. 2012 Jun 1;188(11):5706-12 [PMID: 22544937]
  68. Shock. 2013 Dec;40(6):492-5 [PMID: 24089009]
  69. Circ Cardiovasc Qual Outcomes. 2017 Feb;10(2): [PMID: 28228456]
  70. BMJ. 2016 Apr 19;353:i1753 [PMID: 27094586]
  71. Trends Immunol. 2013 Jul;34(7):317-28 [PMID: 23540649]
  72. Clin Exp Immunol. 2007 Jul;149(1):139-45 [PMID: 17459078]
  73. Pregnancy Hypertens. 2021 Mar;23:1-4 [PMID: 33160129]
  74. FEBS J. 2015 Jun;282(12):2279-95 [PMID: 25903461]
  75. Immunity. 2021 May 11;54(5):875-884 [PMID: 33979585]
  76. Innate Immun. 2015 Nov;21(8):827-46 [PMID: 26403174]
  77. Circ Res. 2020 Jul 3;127(2):269-283 [PMID: 32241223]
  78. Am Heart J. 2008 Nov;156(5):918-30 [PMID: 19061708]
  79. Int J Mol Sci. 2022 Oct 26;23(21): [PMID: 36361701]
  80. PLoS Med. 2020 May 7;17(5):e1003115 [PMID: 32379748]
  81. Arthritis Res Ther. 2006;8(3):R69 [PMID: 16613612]
  82. Cell Rep. 2023 Aug 29;42(8):113006 [PMID: 37610870]
  83. J Clin Med. 2023 Jan 01;12(1): [PMID: 36615135]
  84. J Cell Physiol. 2020 Dec;235(12):9577-9588 [PMID: 32383175]
  85. Biochemistry (Mosc). 2020 Oct;85(10):1178-1190 [PMID: 33202203]
  86. J Immunol. 2022 Feb 15;208(4):968-978 [PMID: 35063996]
  87. Pregnancy Hypertens. 2019 Jul;17:233-240 [PMID: 31487646]
  88. Cardiovasc Res. 2020 Feb 1;116(2):317-328 [PMID: 31119285]
  89. Nat Rev Immunol. 2020 Jun;20(6):375-388 [PMID: 32132681]
  90. J Invest Dermatol. 2016 Apr;136(4):798-808 [PMID: 26807516]
  91. Front Immunol. 2014 Jun 30;5:298 [PMID: 25071761]
  92. Circ Res. 2022 May 13;130(10):1550-1564 [PMID: 35430873]
  93. Proc Natl Acad Sci U S A. 2017 May 23;114(21):5485-5490 [PMID: 28484006]
  94. Circulation. 1997 Nov 4;96(9):3042-7 [PMID: 9386173]
  95. Hypertens Pregnancy. 2020 Nov;39(4):387-392 [PMID: 32507068]
  96. EBioMedicine. 2019 Jan;39:531-539 [PMID: 30579870]
  97. Immunity. 2018 May 15;48(5):951-962.e5 [PMID: 29768178]
  98. Stem Cells. 2012 Jul;30(7):1486-95 [PMID: 22511319]
  99. Arch Med Res. 2011 Jul;42(5):382-91 [PMID: 21843566]
  100. Free Radic Biol Med. 2010 Aug 1;49(3):493-500 [PMID: 20510352]
  101. J Biol Chem. 2010 Oct 22;285(43):32844-32851 [PMID: 20729208]
  102. Sci Rep. 2021 Mar 31;11(1):7281 [PMID: 33790316]
  103. Tissue Antigens. 2014 Sep;84(3):255-63 [PMID: 25132109]
  104. Reprod Biol. 2024 Mar;24(1):100857 [PMID: 38295720]
  105. Pregnancy Hypertens. 2018 Jan;11:18-25 [PMID: 29523268]
  106. Front Immunol. 2023 Jan 10;13:1098725 [PMID: 36703963]
  107. Cardiovasc Res. 2020 Jun 1;116(7):1254-1274 [PMID: 31834409]
  108. Am J Pharm Educ. 2006 Oct 15;70(5):102 [PMID: 17149431]
  109. Int Arch Allergy Immunol. 2013;160(2):152-60 [PMID: 23018521]
  110. Arch Med Sci. 2014 Aug 29;10(4):791-800 [PMID: 25276166]
  111. Eur J Epidemiol. 2013 Jan;28(1):1-19 [PMID: 23397514]
  112. Am J Reprod Immunol. 2024 Aug;92(2):e13908 [PMID: 39119763]
  113. Nat Chem Biol. 2015 Oct;11(10):765-71 [PMID: 26302479]
  114. Am J Obstet Gynecol. 2001 Oct;185(4):792-7 [PMID: 11641653]
  115. Best Pract Res Clin Obstet Gynaecol. 2024 Jun;94:102480 [PMID: 38490067]
  116. Annu Rev Biochem. 2016 Jun 2;85:133-60 [PMID: 27023847]
  117. PLoS One. 2013;8(3):e59989 [PMID: 23527291]
  118. J Reprod Immunol. 2017 Feb;119:91-97 [PMID: 27396500]
  119. Nature. 2015 Oct 29;526(7575):660-5 [PMID: 26375003]
  120. Reprod Biomed Online. 2006 Nov;13(5):680-6 [PMID: 17169180]
  121. Pregnancy Hypertens. 2013 Apr;3(2):58 [PMID: 26105840]
  122. Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17537-42 [PMID: 22988082]
  123. Chem Rev. 2015 Mar 25;115(6):2296-349 [PMID: 25330018]
  124. Reproduction. 2016 Dec;152(6):775-784 [PMID: 27658754]
  125. Clin Immunol. 2017 Apr;177:12-17 [PMID: 26794911]
  126. Front Pharmacol. 2023 Feb 21;14:1109576 [PMID: 36895942]
  127. Pregnancy Hypertens. 2020 Jul;21:159-165 [PMID: 32535227]
  128. PLoS Med. 2008 Oct 21;5(10):e207 [PMID: 18942886]
  129. Placenta. 2021 Sep 15;113:57-66 [PMID: 34053733]
  130. Theranostics. 2021 Mar 5;11(10):5028-5044 [PMID: 33754042]
  131. Front Immunol. 2021 Sep 29;12:746032 [PMID: 34659244]
  132. Nat Rev Nephrol. 2014 Aug;10(8):466-80 [PMID: 25003615]
  133. Br J Obstet Gynaecol. 1995 Nov;102(11):876-81 [PMID: 8534622]
  134. Front Immunol. 2022 Jun 29;13:854202 [PMID: 35844599]
  135. Am J Obstet Gynecol. 2000 Dec;183(6):1558-63 [PMID: 11120528]
  136. J Reprod Immunol. 2022 Feb;149:103470 [PMID: 34972043]
  137. Sci Rep. 2018 Nov 19;8(1):16973 [PMID: 30451917]
  138. Front Cardiovasc Med. 2021 Feb 17;8:640124 [PMID: 33681309]
  139. Proc Natl Acad Sci U S A. 2021 Oct 19;118(42): [PMID: 34663697]
  140. Cell Rep. 2021 Mar 9;34(10):108826 [PMID: 33691121]
  141. Hum Immunol. 2021 May;82(5):362-370 [PMID: 33551128]
  142. Br J Pharmacol. 2019 Jun;176(12):1813-1817 [PMID: 31127619]
  143. Gastroenterology. 2008 Jul;135(1):234-43 [PMID: 18485901]
  144. Am J Obstet Gynecol. 2004 Aug;191(2):525-9 [PMID: 15343231]
  145. J Biol Chem. 2002 Apr 26;277(17):15028-34 [PMID: 11836257]
  146. Cytokine. 2018 May;105:23-31 [PMID: 29438905]
  147. Circ Res. 2018 Mar 2;122(5):664-669 [PMID: 29367213]
  148. Mol Ther. 2024 May 1;32(5):1510-1525 [PMID: 38454605]
  149. J Reprod Immunol. 2017 Feb;119:98-106 [PMID: 27613663]
  150. Nature. 2010 Mar 4;464(7285):104-7 [PMID: 20203610]
  151. J Clin Endocrinol Metab. 2011 May;96(5):E846-50 [PMID: 21367929]
  152. Front Cardiovasc Med. 2015 Apr 28;2:20 [PMID: 26664892]
  153. Eur Heart J. 2014 Mar;35(9):578-89 [PMID: 24026779]

MeSH Term

Humans
Immunity, Innate
Pregnancy
Pre-Eclampsia
Female
Cardiovascular Diseases
Trained Immunity

Word Cloud

Created with Highcharts 10.0.0PEcardiovascularmaternalinnatecharacterizedDAMPsimmunecellslong-termpotentialimmunityTRIMhypertensiondamage-associatedmolecularproinflammatorystatemotherendothelialdysfunctionrisksheartdiseasechronicroletrainedlinkmayhealthpreeclampsiaPreeclampsiacomplexpregnancysyndromewithoutproteinuriaaffecting2-6%pregnanciesgloballyexcessivereleasepatternscirculationDAMP-richmilieuactsinducingelevatedcytokinesIL-1��IL-18placentaresultsstronglyassociateddisordersimmediatefetalwell-documentedaccumulatingevidenceindicatesalsoconfersincludingcoronarystrokefailureunderlyingmechanismsconnectingconditionsremainuncleararticleexploresmechanisticincreasedriskproposepersistentexposureepigeneticallyreprogramprogenitorsleadingreprogrammingenhancesinflammatoryresponsesubsequentstimulipotentiallycontributinginflammationpredisposewomendiseaseslaterlifeUnderstandingprovidenovelinsightspathophysiologyPE-relatedcomplicationsidentifytargetstherapeuticinterventionresearchwarrantedinvestigateepigeneticmetabolicalterationsinduceddeterminechangesinfluenceTrainedfuturepatternmoleculeslong-lastingeffects

Similar Articles

Cited By

No available data.